To the full analysis
Buyback calculator for Cytokinetics
Cytokinetics stock: key metrics
CYTKCytokinetics had an operating margin of −695.4% and a return on invested capital (ROIC) of −38.7% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | −1,961.6% | −1,826.5% |
| 2007 | 100.0% | −414.7% | −358.9% |
| 2008 | 100.0% | −475.7% | −453.9% |
| 2009 | 100.0% | 32.0% | 30.1% |
| 2010 | 100.0% | −1,926.1% | −1,912.6% |
| 2011 | 100.0% | −1,199.1% | −1,196.5% |
| 2012 | −371.5% | −517.3% | −551.4% |
| 2013 | −61.3% | −110.6% | −110.0% |
| 2014 | 5.4% | −31.4% | −31.2% |
| 2015 | −61.9% | −130.5% | −130.9% |
| 2016 | 39.5% | 17.6% | 15.5% |
| 2017 | −575.5% | −848.3% | −955.9% |
| 2018 | −183.0% | −282.3% | −337.4% |
| 2019 | −220.5% | −368.0% | −452.9% |
| 2020 | −73.7% | −168.3% | −228.0% |
| 2021 | −127.1% | −264.5% | −305.7% |
| 2022 | −154.6% | −342.8% | −411.2% |
| 2023 | −4,284.1% | −6,589.7% | −6,988.6% |
| 2024 | −1,737.2% | −2,902.7% | −3,191.1% |
| 2025 | 88.5% | −695.4% | −891.6% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −53.7% | −33.0% | −33.7% |
| 2007 | −48.9% | −31.9% | −31.5% |
| 2008 | −100.0% | −46.8% | −64.5% |
| 2009 | 24.2% | 30.4% | 20.0% |
| 2010 | −69.9% | −44.7% | −63.2% |
| 2011 | −99.3% | −63.2% | −90.7% |
| 2012 | −58.3% | −51.4% | −53.7% |
| 2013 | −61.9% | −41.7% | −40.5% |
| 2014 | −15.9% | −14.1% | −11.0% |
| 2015 | −54.7% | −30.7% | −32.5% |
| 2016 | 17.4% | 16.8% | 9.7% |
| 2017 | −100.0% | −44.6% | −43.3% |
| 2018 | −100.0% | −30.9% | −50.3% |
| 2019 | 200.0% | −34.3% | −42.0% |
| 2020 | −100.0% | −19.4% | −23.8% |
| 2021 | −88.3% | −23.1% | −25.6% |
| 2022 | 200.0% | −30.1% | −38.3% |
| 2023 | 136.2% | −47.1% | −63.8% |
| 2024 | 200.0% | −43.1% | −42.1% |
| 2025 | 119.0% | −38.7% | −55.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2017)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.